Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Quijada-Álamo, Miguel; Freed, Grace; Wagenblast, Elvin

doi:10.1158/2643-3230.BCD-25-0036

Article navigation

In Focus| April 27 2025

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Miguel Quijada-Álamo

0000-0002-4831-4565

;

Miguel Quijada-Álamo

1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Grace Freed

0000-0002-3360-958X

;

Grace Freed

1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Elvin Wagenblast

0000-0002-0709-2759

Elvin Wagenblast *

1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.

6Division of Pediatric Hematology-Oncology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.

*Corresponding Author: Elvin Wagenblast, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029. E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Elvin Wagenblast, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029. E-mail: [email protected]

Blood Cancer Discov 2025;XX:1–5

Received: February 20 2025

Revision Received: April 04 2025

Accepted: April 09 2025

Online ISSN: 2643-3249

Print ISSN: 2643-3230

2025

American Association for Cancer Research

Blood Cancer Discov OF1–OF5.

https://doi.org/10.1158/2643-3230.BCD-25-0036

Summary:

Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

This content is only available via PDF.

2025

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Summary:

Citing articles via

Email alerts

AACR Journals

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies Available to Purchase

Summary:

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies